Solid Biosciences Inc.
SLDB- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001707502
No open-market purchases or sales by Solid Biosciences Inc. insiders were filed in the last 90 days; 157 institutions reported holding it in 13F filings for Q2 2026, worth $1.14B in total; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Solid Biosciences Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Solid Biosciences Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Smith Ian F | Director | 138,145 | Jul 7, 2026 | 5 |
| Edelman Joseph | Director, 10% Owner | 11,833,539Indirect | Jun 11, 2026 | 2 |
| Perceptive Advisors LLC | Director, 10% Owner | 11,833,539Indirect | Jun 11, 2026 | 2 |
| Perceptive Life Sciences Master Fund Ltd | Director, 10% Owner | 11,833,539Indirect | Jun 11, 2026 | 2 |
| Nagendran Sukumar | Director | – | Jun 11, 2026 | 1 |
| Freed Martin I | Director | – | Jun 11, 2026 | 1 |
| Stone Adam Leo | Director | – | Jun 11, 2026 | 1 |
| Ganot Ilan | Director | 27,474Indirect | Jun 11, 2026 | 7 |
| Sullivan Lynne Marie | Director | – | Jun 11, 2026 | 1 |
| Keresty Georgia | Director | – | Jun 11, 2026 | 1 |
| Kahn Clare | Director | 2,960 | Jun 11, 2026 | 1 |
| Howton David T | Chief Operating Officer | 105,077 | Apr 21, 2026 | 5 |
| Cumbo Alexander | President and CEO | 235,405 | Apr 21, 2026 | 5 |
| Tan Kevin | CFO & Treasurer | 99,422 | Apr 21, 2026 | 5 |
| Hanrahan Jessie | Chief Regulatory Officer | 74,318 | Apr 21, 2026 | 5 |
| Herzich Paul | Chief Technology Officer | 72,638 | Apr 21, 2026 | 5 |
| Brooks Gabriel | Chief Medical Officer | 89,466 | Apr 21, 2026 | 5 |
| BCIP Life Sciences Associates, LP | 10% Owner | 5,034,582Indirect | Feb 21, 2025 | 0 |
| Bain Capital Life Sciences Partners, LP | 10% Owner | 5,034,582Indirect | Feb 21, 2025 | 0 |
| Bain Capital Life Sciences Investors, LLC | 10% Owner | 5,034,582Indirect | Feb 21, 2025 | 0 |
| BCLS SB Investco, LP | 10% Owner | 5,034,582Indirect | Feb 21, 2025 | 0 |
| Bain Capital Life Sciences Fund II, L.P. | 10% Owner | 5,034,582Indirect | Feb 21, 2025 | 0 |
| Bain Capital Life Sciences Investors II, LLC | 10% Owner | 5,034,582Indirect | Feb 21, 2025 | 0 |
| BCLS II Equity Opportunities, LP | 10% Owner | 5,034,582Indirect | Feb 21, 2025 | 0 |
| BCLS II Investco, LP | 10% Owner | 5,034,582Indirect | Feb 21, 2025 | 0 |
| BCLS II Investco (GP), LLC | 10% Owner | 5,034,582Indirect | Feb 21, 2025 | 0 |
| BCLS II Equity Opportunities GP, LLC | 10% Owner | 5,034,582Indirect | Feb 21, 2025 | 0 |
| Perceptive Xontogeny Venture Fund, LP | Director, 10% Owner | 11,833,539Indirect | Feb 21, 2025 | 0 |
| RA Capital Healthcare Fund LP | 10% Owner | 4,192,216Indirect | Feb 21, 2025 | 0 |
| Ra Capital Management, L.P. | 10% Owner | 4,192,216Indirect | Feb 21, 2025 | 0 |
| Kolchinsky Peter | 10% Owner | 4,192,216Indirect | Feb 21, 2025 | 0 |
| Shah Rajeev M. | 10% Owner | 4,192,216Indirect | Feb 21, 2025 | 0 |
| Atchinson Robert | 10% Owner | 4,248,084Indirect | Feb 19, 2025 | 0 |
| Gross Phillip | 10% Owner | 4,248,084Indirect | Feb 19, 2025 | 0 |
| Adage Capital Management, L.P. | 10% Owner | 4,248,084Indirect | Feb 19, 2025 | 0 |
| Marlowe Jennifer | CSO | 6,998 | Feb 16, 2024 | 0 |
| RA Capital Nexus Fund, L.P. | Director, 10% Owner | 4,192,216Indirect | Jan 12, 2024 | 0 |
| Koppel Adam | Director, 10% Owner | 4,034,582Indirect | Jan 12, 2024 | 0 |
| Morris Carl Ashley | Chief Scientific Officer | 19,760 | Jan 31, 2023 | 0 |
| Huffines Robert Luther | Director | – | Dec 15, 2022 | 0 |
| Perceptive Venture Advisors, LLC | Director, 10% Owner | 73,107Indirect | Dec 6, 2022 | 0 |
| Brennan Erin Powers | Chief Legal Officer, Secretary | – | May 4, 2022 | 0 |
| Schneider Joel Solomon Zev | Chief Operating Officer | 236,270 | Mar 15, 2022 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Feb 18, 2026 (view filing) | Feb 18 | Same day | Cumbo AlexanderPresident and CEO | SSale | −16.6K | $5.82 | −$96.9K | −6.6%235.4K after | 10b5-1 |
| Feb 18, 2026 (view filing) | Feb 18 | Same day | Hanrahan JessieChief Regulatory Officer | SSale | −4.13K | $5.82 | −$24.1K | −5.3%74.3K after | 10b5-1 |
| Feb 18, 2026 (view filing) | Feb 18 | Same day | Ganot IlanDirector | SSale | −2.66K | $5.82 | −$15.5K | −8.8%27.5K after | 10b5-1 |
| Feb 18, 2026 (view filing) | Feb 18 | Same day | Herzich PaulChief Technology Officer | SSale | −3.62K | $5.82 | −$21.0K | −4.7%72.6K after | 10b5-1 |
| Feb 18, 2026 (view filing) | Feb 18 | Same day | Howton David TChief Operating Officer | SSale | −7.47K | $5.82 | −$43.5K | −6.6%105.1K after | 10b5-1 |
| Feb 18, 2026 (view filing) | Feb 18 | Same day | Brooks GabrielChief Medical Officer | SSale | 0 | – | $0 | 0.0%89.5K after | 10b5-1 |
| Feb 18, 2026 (view filing) | Feb 18 | Same day | Tan KevinCFO & Treasurer | SSale | −5.40K | $5.82 | −$31.5K | −5.2%99.4K after | 10b5-1 |
| Feb 6, 2026 (view filing) | Feb 4 | 2 days | Howton David TChief Operating Officer | SSale | −18.9K | $6.44 | −$121.7K | −16.2%97.9K after | 10b5-1 |
| Feb 6, 2026 (view filing) | Feb 4 | 2 days | Cumbo AlexanderPresident and CEO | SSale | −48.9K | $6.44 | −$315.0K | −18.1%222.0K after | 10b5-1 |
| Feb 6, 2026 (view filing) | Feb 4 | 2 days | Ganot IlanDirector | SSale | −7.21K | $6.44 | −$46.4K | −22.2%25.3K after | 10b5-1 |
| Feb 6, 2026 (view filing) | Feb 4 | 2 days | Tan KevinCFO & Treasurer | SSale | −14.8K | $6.44 | −$95.2K | −13.6%94.2K after | 10b5-1 |
| Feb 6, 2026 (view filing) | Feb 4 | 2 days | Brooks GabrielChief Medical Officer | SSale | −12.6K | $6.44 | −$81.2K | −13.0%84.1K after | 10b5-1 |
| Feb 6, 2026 (view filing) | Feb 4 | 2 days | Hanrahan JessieChief Regulatory Officer | SSale | −12.3K | $6.44 | −$79.5K | −14.9%70.3K after | 10b5-1 |
| Feb 6, 2026 (view filing) | Feb 4 | 2 days | Herzich PaulChief Technology Officer | SSale | −10.9K | $6.44 | −$70.2K | −13.6%69.1K after | 10b5-1 |
| Feb 2, 2026 (view filing) | Feb 2 | Same day | Tan KevinCFO & Treasurer | SSale | −26.8K | $6.44 | −$172.8K | −19.8%109.0K after | 10b5-1 |
| Feb 2, 2026 (view filing) | Feb 2 | Same day | Cumbo AlexanderPresident and CEO | SSale | −80.3K | $6.44 | −$516.9K | −22.9%270.9K after | 10b5-1 |
| Feb 2, 2026 (view filing) | Feb 2 | Same day | Hanrahan JessieChief Regulatory Officer | SSale | −26.5K | $6.44 | −$170.9K | −24.3%82.7K after | 10b5-1 |
| Feb 2, 2026 (view filing) | Feb 2 | Same day | Brooks GabrielChief Medical Officer | SSale | −28.3K | $6.44 | −$182.5K | −22.7%96.7K after | 10b5-1 |
| Feb 2, 2026 (view filing) | Feb 2 | Same day | Howton David TChief Operating Officer | SSale | −37.8K | $6.44 | −$243.2K | −24.4%116.8K after | 10b5-1 |
| Feb 2, 2026 (view filing) | Feb 2 | Same day | Herzich PaulChief Technology Officer | SSale | −26.3K | $6.44 | −$169.1K | −24.7%80.0K after | 10b5-1 |
| Jan 30, 2026 (view filing) | Jan 28 | 2 days | Ganot IlanDirector | SSale | −191 | $6.59 | −$1.26K | −1.1%17.5K after | 10b5-1 |
| Jan 13, 2026 (view filing) | Jan 13 | Same day | Tan KevinCFO & Treasurer | SSale | −5.70K | $5.27 | −$30.1K | −11.0%46.1K after | 10b5-1 |
| Jan 6, 2026 (view filing) | Jan 5 | 1 day | Ganot IlanDirector | SSale | −1.05K | $5.43 | −$5.72K | −5.7%17.3K after | |
| Dec 4, 2025 (view filing) | Dec 3 | 1 day | Howton David TChief Operating Officer | SSale | −4.93K | $5.11 | −$25.2K | −13.0%32.9K after | 10b5-1 |
| Dec 4, 2025 (view filing) | Dec 3 | 1 day | Cumbo AlexanderPresident and CEO | SSale | −10.8K | $5.11 | −$55.2K | −11.7%81.4K after | 10b5-1 |
| Dec 4, 2025 (view filing) | Dec 3 | 1 day | Hanrahan JessieChief Regulatory Officer | SSale | −4.48K | $5.11 | −$22.9K | −14.4%26.7K after | 10b5-1 |
| Dec 4, 2025 (view filing) | Dec 3 | 1 day | Herzich PaulChief Technology Officer | SSale | −2.70K | $5.11 | −$13.8K | −9.2%26.6K after | 10b5-1 |
| Nov 13, 2025 (view filing) | Nov 10 | 3 days | Ganot IlanDirector | SSale | −3.28K | $4.12 | −$13.5K | −3.3%95.4K after | |
| Oct 21, 2025 (view filing) | Oct 20 | 1 day | Brooks GabrielChief Medical Officer | SSale | −2.90K | $5.96 | −$17.3K | −7.9%33.8K after | |
| Mar 13, 2025 (view filing) | Mar 11 | 2 days | Kahn ClareDirector | PPurchase | +1.86K | $5.34 | +$9.93K | +169.1%2.96K after | |
| Feb 21, 2025 (view filing)5:48 PM ET | Feb 19 | 2 days | BCIP Life Sciences Associates, LP and 9 others10% Owner | PPurchase | +1.00M | $4.03 | +$4.03M | +24.8%5.03M after | |
| Feb 21, 2025 (view filing)5:48 PM ET | Feb 19 | 2 days | BCIP Life Sciences Associates, LP and 9 others10% Owner | PPurchase | +6.44M | $4.03 | +$26.0M | –6.44M after | Derivative |
| Feb 21, 2025 (view filing)4:17 PM ET | Feb 19 | 2 days | Edelman Joseph and 3 othersDirector, 10% Owner | PPurchase | +5.00M | $4.03 | +$20.1M | +73.2%11.8M after | |
| Feb 21, 2025 (view filing)4:11 PM ET | Feb 19 | 2 days | RA Capital Healthcare Fund LP and 3 others10% Owner | PPurchase | +3.72M | $4.03 | +$15.0M | –3.72M after | Derivative |
| Feb 19, 2025 (view filing)4:16 PM ET | Feb 18 | 1 day | Atchinson Robert and 2 others10% Owner | PPurchaseCommon Stock, $0.001 par value per share | +252.5K | $7.56 | +$1.91M | +6.3%4.25M after | |
| Feb 18, 2025 (view filing) | Feb 14 | 4 days | Hanrahan JessieChief Regulatory Officer | SSale | −3.08K | $3.96 | −$12.2K | −13.8%19.3K after | 10b5-1 |
| Feb 18, 2025 (view filing) | Feb 14 | 4 days | Brooks GabrielChief Medical Officer | SSale | −3.26K | $3.96 | −$12.9K | −12.5%22.8K after | 10b5-1 |
| Feb 18, 2025 (view filing) | Feb 14 | 4 days | Tan KevinCFO & Treasurer | SSale | −3.16K | $3.96 | −$12.5K | −8.9%32.3K after | 10b5-1 |
| Feb 18, 2025 (view filing) | Feb 14 | 4 days | Herzich PaulChief Technology Officer | SSale | −2.69K | $3.96 | −$10.6K | −12.8%18.4K after | 10b5-1 |
| Feb 18, 2025 (view filing) | Feb 14 | 4 days | Cumbo AlexanderPresident and CEO | SSale | −11.4K | $3.96 | −$45.0K | −15.8%60.7K after | 10b5-1 |
| Feb 18, 2025 (view filing) | Feb 14 | 4 days | Ganot IlanDirector | SSale | −1.71K | $3.96 | −$6.78K | −10.3%14.8K after | 10b5-1 |
| Feb 18, 2025 (view filing) | Feb 14 | 4 days | Howton David TChief Operating Officer | SSale | −5.56K | $3.96 | −$22.0K | −18.3%24.8K after | 10b5-1 |
| Jan 29, 2025 (view filing) | Jan 28 | 1 day | Ganot IlanDirector | SSale | −144 | $3.11 | −$447.84 | −1.2%11.7K after | 10b5-1 |
| Jan 13, 2025 (view filing) | Jan 10 | 3 days | Tan KevinCFO & Treasurer | SSale | −4.07K | $3.89 | −$15.8K | −14.1%24.8K after | |
| Jan 7, 2025 (view filing) | Jan 6 | 1 day | Ganot IlanDirector | SSale | −1.06K | $4.31 | −$4.55K | −8.4%11.4K after | |
| Dec 4, 2024 (view filing) | Dec 3 | 1 day | Hanrahan JessieChief Regulatory Officer | SSale | −4.61K | $5.60 | −$25.8K | −24.5%14.2K after | |
| Dec 4, 2024 (view filing) | Dec 3 | 1 day | Cumbo AlexanderPresident and CEO | SSale | −11.1K | $5.60 | −$62.2K | −22.4%38.5K after | |
| Dec 4, 2024 (view filing) | Dec 3 | 1 day | Howton David TChief Operating Officer | SSale | −5.07K | $5.60 | −$28.4K | −24.5%15.7K after | |
| Dec 4, 2024 (view filing) | Dec 3 | 1 day | Herzich PaulChief Technology Officer | SSale | −2.78K | $5.60 | −$15.6K | −18.6%12.2K after | |
| Oct 22, 2024 (view filing) | Oct 21 | 1 day | Brooks GabrielChief Medical Officer | SSale | −2.92K | $6.50 | −$19.0K | −21.0%11.0K after |